325 related articles for article (PubMed ID: 2953870)
61. Secondary treatment of advanced cancer of the prostate with Zoladex.
Klarskov P; Lund F; Petersen SE
Int Urol Nephrol; 1990; 22(4):359-62. PubMed ID: 2146234
[TBL] [Abstract][Full Text] [Related]
62. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
[TBL] [Abstract][Full Text] [Related]
63. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
64. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
65. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
[No Abstract] [Full Text] [Related]
66. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group.
Kaufmann M; Jonat W; Schachner-Wünschmann E; Bastert G; Maass H
Onkologie; 1991 Feb; 14(1):22-4, 26-8, 30. PubMed ID: 1829149
[TBL] [Abstract][Full Text] [Related]
67. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
68. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
[TBL] [Abstract][Full Text] [Related]
69. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer.
Waxman J; Sandow J; Thomas H; James N; Williams G
Cancer Chemother Pharmacol; 1989; 25(3):219-20. PubMed ID: 2513141
[TBL] [Abstract][Full Text] [Related]
70. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
[TBL] [Abstract][Full Text] [Related]
71. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
Citrin DL; Resnick MI; Guinan P; al-Bussam N; Scott M; Gau TC; Kennealey GT
Prostate; 1991; 18(2):139-46. PubMed ID: 1826048
[TBL] [Abstract][Full Text] [Related]
72. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
[TBL] [Abstract][Full Text] [Related]
73. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
J Urol; 1991 Nov; 146(5):1321-6. PubMed ID: 1834864
[TBL] [Abstract][Full Text] [Related]
74. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
75. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
Wenderoth UK; Jacobi GH
Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
[TBL] [Abstract][Full Text] [Related]
76. [Phase I study with LH-RH agonist, ICI 118630].
Usami M; Kotake T; Sonoda T
Hinyokika Kiyo; 1986 Mar; 32(3):493-501. PubMed ID: 2942018
[TBL] [Abstract][Full Text] [Related]
77. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Chodak GW
Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
[TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
[TBL] [Abstract][Full Text] [Related]
79. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
[TBL] [Abstract][Full Text] [Related]
80. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
Kaisary AV; Tyrrell CJ; Peeling WB; Griffiths K
Br J Urol; 1991 May; 67(5):502-8. PubMed ID: 1828183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
